<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35632408</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>21</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">652</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines10050652</ELocationID><Abstract><AbstractText Label="UNLABELLED">Long COVID is a multi-system syndrome following SARS-CoV-2 infection with persistent symptoms of at least 4 weeks, and frequently for several months. It has been suggested that there may be an autoimmune component. There has been an understandable caution amongst some people experiencing long COVID that, by boosting their immune response, a COVID vaccine may exacerbate their symptoms. We aimed to survey people living with long COVID, evaluating the impact of their first COVID vaccination on their symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with long COVID were invited to complete a web-based questionnaire through postings on social media and direct mailing from support groups. Basic demographics, range and severity of long COVID symptoms, before and after their vaccine, were surveyed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">900 people participated in the questionnaire, of whom 45 had pre-existing myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) but no evidence of COVID infection, and a further 43 did not complete the survey in full. The demographics and symptomology of the remaining 812 people were similar to those recorded by the UK Office of National Statistics. Following vaccination, 57.9% of participants reported improvements in symptoms, 17.9% reported deterioration and the remainder no change. There was considerable individual variation in responses. Larger improvements in symptom severity scores were seen in those receiving the mRNA vaccines compared to adenoviral vector vaccines.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our survey suggests COVID-19 vaccination may improve long COVID patients, on average. The observational nature of the survey limits drawing direct causal inference, but requires validation with a randomised controlled trial.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strain</LastName><ForeName>William David</ForeName><Initials>WD</Initials><Identifier Source="ORCID">0000-0002-6826-418X</Identifier><AffiliationInfo><Affiliation>Diabetes and Vascular Research Centre, University of Exeter Medical School, Barrack Road, Exeter EX2 5AX, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Department of Healthcare for Older People, Royal Devon &amp; Exeter Hospital Barrack Road, Exeter EX2 5DW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherwood</LastName><ForeName>Ondine</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-4421-2382</Identifier><AffiliationInfo><Affiliation>LongCovidSOS, Patient Advocacy Group, Surrey, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Amitava</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London Hospitals NHS Trust, London NW1 2DA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van der Togt</LastName><ForeName>Vicky</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Research-Aid Networks, Chicago, IL 60605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hishmeh</LastName><ForeName>Lyth</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>LongCovidSOS, Patient Advocacy Group, Surrey, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossman</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6124-4103</Identifier><AffiliationInfo><Affiliation>Research-Aid Networks, Chicago, IL 60605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biosciences, University of Kent, Kent CT2 7NJ, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">survey</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>28</Day><Hour>1</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35632408</ArticleId><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="doi">10.3390/vaccines10050652</ArticleId><ArticleId IdType="pii">vaccines10050652</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>O&#x2019;Sullivan O. Long-term sequelae following previous coronavirus epidemics. Clin. Med. 2021;21:e68&#x2013;e70. doi: 10.7861/clinmed.2020-0204.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0204</ArticleId><ArticleId IdType="pmc">PMC7850177</ArticleId><ArticleId IdType="pubmed">33144403</ArticleId></ArticleIdList></Reference><Reference><Citation>Etard J.F., Sow M.S., Leroy S., Toure A., Taverne B., Keita A.K., Msellati P., Magassouba N., Baize S., Raoul H., et al. Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): An observational cohort study. Lancet Infect. Dis. 2017;17:545&#x2013;552. doi: 10.1016/S1473-3099(16)30516-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(16)30516-3</ArticleId><ArticleId IdType="pubmed">28094208</ArticleId></ArticleIdList></Reference><Reference><Citation>van Aalst M., Nelen C.M., Goorhuis A., Stijnis C., Grobusch M.P. Long-term sequelae of chikungunya virus disease: A systematic review. Travel Med. Infect. Dis. 2017;15:8&#x2013;22. doi: 10.1016/j.tmaid.2017.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2017.01.004</ArticleId><ArticleId IdType="pubmed">28163198</ArticleId></ArticleIdList></Reference><Reference><Citation>Worldometer  COVID-19 Coronavirus Pandemic.  [(accessed on 23 March 2022)].  Available online:  https://www.worldometers.info/coronavirus/</Citation></Reference><Reference><Citation>Ayoubkhani D., Munro M. Prevalence of Ongoing Symptoms Following Coronavirus (COVID-19) Infection in the UK.  [(accessed on 23 March 2022)]; Available online:  https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/3march2022.</Citation></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Weerahandi H., Hochman K.A., Simon E., Blaum C., Chodosh J., Duan E., Garry K., Kahan T., Karmen-Tuohy S.L., Karpel H.C., et al. Post-Discharge Health Status and Symptoms in Patients with Severe COVID-19. J. Gen. Intern. Med. 2021;36:738&#x2013;745. doi: 10.1007/s11606-020-06338-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-020-06338-4</ArticleId><ArticleId IdType="pmc">PMC7808113</ArticleId><ArticleId IdType="pubmed">33443703</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B., Mohn K.G., Brokstad K.A., Zhou F., Linchausen D.W., Hansen B.A., Lartey S., Onyango T.B., Kuwelker K., Saevik M., et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 2021;27:1607&#x2013;1613. doi: 10.1038/s41591-021-01433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F., Perego E. How and why patients made Long Covid. Soc. Sci. Med. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE  . COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19 NICE Guideline [NG188] National Institute of Health Care Excellence; 2020.  [(accessed on 13 December 2021)].  Available online:  https://www.nice.org.uk/guidance/ng188.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation  A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus.  [(accessed on 13 December 2021)]; Available online:  https://apps.who.int/iris/bitstream/handle/10665/345824/WHO-2019-nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1-eng.pdf?sequence=1&amp;isAllowed=y.</Citation></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re&#x2019;em Y., Redfield S., Austin J.P., Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>McCorkell L., Assaf G.S., Davis H.E., Wei H., Akrami A. Patient-Led Research Collaborative: Embedding patients in the Long COVID narrative. Pain Rep. 2021;6:e913. doi: 10.1097/PR9.0000000000000913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PR9.0000000000000913</ArticleId><ArticleId IdType="pmc">PMC8112577</ArticleId><ArticleId IdType="pubmed">33987484</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladds E., Rushforth A., Wieringa S., Taylor S., Rayner C., Husain L., Greenhalgh T. Persistent symptoms after Covid-19: Qualitative study of 114 "long Covid" patients and draft quality principles for services. BMC Health Serv. Res. 2020;20:1144. doi: 10.1186/s12913-020-06001-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-020-06001-y</ArticleId><ArticleId IdType="pmc">PMC7750006</ArticleId><ArticleId IdType="pubmed">33342437</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann D.M., Boyton R.J. Decoding the unknowns in long covid. BMJ. 2021;372:n132. doi: 10.1136/bmj.n132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n132</ArticleId><ArticleId IdType="pubmed">33541867</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeting the challenge of long COVID.  [(accessed on 13 December 2021)];Nat. Med. 2020 26:1803. Available online:  https://www.nature.com/articles/s41591-020-01177-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33288947</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D., Crooks M., Gabbay M., Brady M., Hishmeh L., et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study. BMJ Open. 2021;11:e048391. doi: 10.1136/bmjopen-2020-048391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048391</ArticleId><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol. Rep. 2021;9:e14726. doi: 10.14814/phy2.14726.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.14726</ArticleId><ArticleId IdType="pmc">PMC7849453</ArticleId><ArticleId IdType="pubmed">33523608</ArticleId></ArticleIdList></Reference><Reference><Citation>Medical Research Council  Do I Need NHS REC Review?  [(accessed on 15 March 2021)]; Available online:  http://www.hra-decisiontools.org.uk/ethics/engset1.html.</Citation></Reference><Reference><Citation>Cupples L.A., Heeren T., Schatzkin A., Colton T. Multiple testing of hypotheses in comparing two groups. Ann. Intern. Med. 1984;100:122&#x2013;129. doi: 10.7326/0003-4819-100-1-122.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-100-1-122</ArticleId><ArticleId IdType="pubmed">6691637</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman K.J. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43&#x2013;46. doi: 10.1097/00001648-199001000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001648-199001000-00010</ArticleId><ArticleId IdType="pubmed">2081237</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D.T., Milne A., Samms E., Stadon L., Maskell N.A., Hamilton F.W. Are vaccines safe in patients with Long COVID? A prospective observational study. medRxiv. 2021 doi: 10.1101/2021.03.11.21253225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.11.21253225</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J.R., Husain M., Harrison P.J. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18:e1003773. doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. Do vaccines protect from long COVID? Lancet Respir. Med. 2022;10:e30. doi: 10.1016/S2213-2600(22)00020-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00020-0</ArticleId><ArticleId IdType="pmc">PMC8776281</ArticleId><ArticleId IdType="pubmed">35065716</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency  The Effectiveness of Vaccination against Long COVID: A Rapid Evidence Briefing.  [(accessed on 13 December 2021)]; Available online:  https://ukhsa.koha-ptfs.co.uk/cgi-bin/koha/opac-retrieve-file.pl?id=fe4f10cd3cd509fe045ad4f72ae0dfff.</Citation></Reference><Reference><Citation>Ortona E., Buonsenso D., Carfi A., Malorni W., Long Covid Kids study g. Long COVID: An estrogen-associated autoimmune disease? Cell Death Discov. 2021;7:77. doi: 10.1038/s41420-021-00464-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-021-00464-6</ArticleId><ArticleId IdType="pmc">PMC8042352</ArticleId><ArticleId IdType="pubmed">33850105</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Mak J.W.Y., Su Q., Yeoh Y.K., Lui G.C., Ng S.S.S., Zhang F., Li A.Y.L., Lu W., Hui D.S., et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71:544&#x2013;552. doi: 10.1136/gutjnl-2021-325989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>